-
Autor
Apperley, Jane F 1 Baccarani, Michele 1 Conti, Rena M 1 Dusetzina, Stacie B 1 Eigendorff, Ekkehard 1 Guilhot, Francois 1 Guilhot, Joelle 1 Hehlmann, Rudiger 1 Hehlmann, Rüdiger 1 Larson, Richard A 1 Mahon, Francois-Xavier 1 Martinelli, Giovanni 1 Mayer, Jiri 1 Müller, Martin C 1 Niederwieser, Dietger 1 Padula, William V 1 Saussele, Susanne 1 Schiffer, Charles A 1 Silver, Richard T 1 Simonsson, Bengt 1
-
Pracoviště
Barbara Ann Karmanos Cancer Institute... 1 Department of Haematology Hammersmith... 1 Department of Haematology and Oncolog... 1 Department of Haematology and Oncolog... 1 Department of Health Policy and Manag... 1 Department of Hematology and Oncology... 1 Department of Internal Medicine Hemat... 1 Department of Medicine University of ... 1 Department of Medicine University of ... 1 Department of Medicine Weill Cornell ... 1 Eshelman School of Pharmacy and Gilli... 1 INSERM Centre d'Investigation Clinique 1 Laboratoire d'Hematologie Universite ... 1 Uppsala University Uppsala Sweden 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Zeměpisné označení
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Autor
Apperley, Jane F 1 Baccarani, Michele 1 Conti, Rena M 1 Dusetzina, Stacie B 1 Eigendorff, Ekkehard 1 Guilhot, Francois 1 Guilhot, Joelle 1 Hehlmann, Rudiger 1 Hehlmann, Rüdiger 1 Larson, Richard A 1 Mahon, Francois-Xavier 1 Martinelli, Giovanni 1 Mayer, Jiri 1 Müller, Martin C 1 Niederwieser, Dietger 1 Padula, William V 1 Saussele, Susanne 1 Schiffer, Charles A 1 Silver, Richard T 1 Simonsson, Bengt 1
-
Pracoviště
Barbara Ann Karmanos Cancer Institute... 1 Department of Haematology Hammersmith... 1 Department of Haematology and Oncolog... 1 Department of Haematology and Oncolog... 1 Department of Health Policy and Manag... 1 Department of Hematology and Oncology... 1 Department of Internal Medicine Hemat... 1 Department of Medicine University of ... 1 Department of Medicine University of ... 1 Department of Medicine Weill Cornell ... 1 Eshelman School of Pharmacy and Gilli... 1 INSERM Centre d'Investigation Clinique 1 Laboratoire d'Hematologie Universite ... 1 Uppsala University Uppsala Sweden 1
- Formát
- Publikační typ
- Check Tag
- Kategorie
- Zeměpisné označení
- Jazyk
- Země
- Časopis/zdroj
- Dostupnost
- Vlastník
-
Padula, William V
Autor Padula, William V Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD (WVP) Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC (SBD) Department of Haematology, Hammersmith Hospital, Imperial College, London, UK (JFA) Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna, Bologna, Italy Department of Haematology and Oncology, University Hospital, Jena, Germany (EE) INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG) Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM) Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (JM) Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany (DN) Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI (CAS) Department of Medicine, Weill Cornell Medical Center, New York, NY (RTS) Uppsala University, Uppsala, Sweden (BS)
-
Larson, Richard A
Autor Larson, Richard A Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD (WVP) Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC (SBD) Department of Haematology, Hammersmith Hospital, Imperial College, London, UK (JFA) Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna, Bologna, Italy Department of Haematology and Oncology, University Hospital, Jena, Germany (EE) INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG) Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM) Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (JM) Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany (DN) Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI (CAS) Department of Medicine, Weill Cornell Medical Center, New York, NY (RTS) Uppsala University, Uppsala, Sweden (BS)
-
Dusetzina, Stacie B
Autor Dusetzina, Stacie B Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD (WVP) Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC (SBD) Department of Haematology, Hammersmith Hospital, Imperial College, London, UK (JFA) Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna, Bologna, Italy Department of Haematology and Oncology, University Hospital, Jena, Germany (EE) INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG) Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM) Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (JM) Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany (DN) Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI (CAS) Department of Medicine, Weill Cornell Medical Center, New York, NY (RTS) Uppsala University, Uppsala, Sweden (BS)
-
Apperley, Jane F
Autor Apperley, Jane F Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD (WVP) Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC (SBD) Department of Haematology, Hammersmith Hospital, Imperial College, London, UK (JFA) Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna, Bologna, Italy Department of Haematology and Oncology, University Hospital, Jena, Germany (EE) INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG) Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM) Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (JM) Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany (DN) Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI (CAS) Department of Medicine, Weill Cornell Medical Center, New York, NY (RTS) Uppsala University, Uppsala, Sweden (BS)
-
Hehlmann, Rudiger
Autor Hehlmann, Rudiger Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD (WVP) Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC (SBD) Department of Haematology, Hammersmith Hospital, Imperial College, London, UK (JFA) Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna, Bologna, Italy Department of Haematology and Oncology, University Hospital, Jena, Germany (EE) INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG) Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM) Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (JM) Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany (DN) Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI (CAS) Department of Medicine, Weill Cornell Medical Center, New York, NY (RTS) Uppsala University, Uppsala, Sweden (BS)
-
Baccarani, Michele
Autor Baccarani, Michele Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD (WVP) Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC (SBD) Department of Haematology, Hammersmith Hospital, Imperial College, London, UK (JFA) Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna, Bologna, Italy Department of Haematology and Oncology, University Hospital, Jena, Germany (EE) INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG) Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM) Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (JM) Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany (DN) Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI (CAS) Department of Medicine, Weill Cornell Medical Center, New York, NY (RTS) Uppsala University, Uppsala, Sweden (BS)
-
Eigendorff, Ekkehard
Autor Eigendorff, Ekkehard Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD (WVP) Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC (SBD) Department of Haematology, Hammersmith Hospital, Imperial College, London, UK (JFA) Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna, Bologna, Italy Department of Haematology and Oncology, University Hospital, Jena, Germany (EE) INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG) Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM) Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (JM) Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany (DN) Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI (CAS) Department of Medicine, Weill Cornell Medical Center, New York, NY (RTS) Uppsala University, Uppsala, Sweden (BS)
-
Guilhot, Joelle
Autor Guilhot, Joelle Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD (WVP) Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC (SBD) Department of Haematology, Hammersmith Hospital, Imperial College, London, UK (JFA) Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna, Bologna, Italy Department of Haematology and Oncology, University Hospital, Jena, Germany (EE) INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG) Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM) Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (JM) Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany (DN) Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI (CAS) Department of Medicine, Weill Cornell Medical Center, New York, NY (RTS) Uppsala University, Uppsala, Sweden (BS)
-
Guilhot, Francois
Autor Guilhot, Francois Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD (WVP) Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC (SBD) Department of Haematology, Hammersmith Hospital, Imperial College, London, UK (JFA) Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna, Bologna, Italy Department of Haematology and Oncology, University Hospital, Jena, Germany (EE) INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG) Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM) Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (JM) Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany (DN) Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI (CAS) Department of Medicine, Weill Cornell Medical Center, New York, NY (RTS) Uppsala University, Uppsala, Sweden (BS)
-
Hehlmann, Rüdiger, 1941-
Autor Autorita Department of Health Policy and Management, Johns Hopkins University, Baltimore, MD (WVP) Department of Medicine (RAL) and Departments of Pediatrics and of Public Health Sciences (RMC), University of Chicago, Chicago, IL Eshelman School of Pharmacy and Gillings School of Global Public Health, Lineberger Comprehensive Cancer Center, and Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill, NC (SBD) Department of Haematology, Hammersmith Hospital, Imperial College, London, UK (JFA) Department of Medicine (RH, SS) and Department of Hematology and Oncology (MCM), University of Heidelberg, Mannheim, Germany Department of Haematology and Oncology, S. Orsola-Malpighi University Hospital (MB), and Department of Hematology, "L. e A. Seragnoli" (GM), University of Bologna, Bologna, Italy Department of Haematology and Oncology, University Hospital, Jena, Germany (EE) INSERM Centre d'Investigation Clinique (CIC) 1402, CHU de Poitiers, Poitiers, France (JG, FG) Laboratoire d'Hematologie, Universite Victor Segalen, Bordeaux, Pessac, France (FXM) Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic (JM) Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany (DN) Barbara Ann Karmanos Cancer Institute, Wayne State University, Detroit, MI (CAS) Department of Medicine, Weill Cornell Medical Center, New York, NY (RTS) Uppsala University, Uppsala, Sweden (BS)
Open Access Digital Library od 1996-01-01
PubMed
26944912
DOI
10.1093/jnci/djw003
Knihovny.cz E-zdroje
BACKGROUND: We analyzed the cost-effectiveness of treating incident chronic myeloid leukemia in chronic phase (CML-CP) with generic imatinib when it becomes available in United States in 2016. In the year following generic entry, imatinib's price is expected to drop 70% to 90%. We hypothesized that initiating treatment with generic imatinib in these patients and then switching to the other tyrosine-kinase inhibitors (TKIs), dasatinib or nilotinib, because of intolerance or lack of effectiveness ("imatinib-first") would be cost-effective compared with the current standard of care: "physicians' choice" of initiating treatment with any one of the three TKIs. METHODS: We constructed Markov models to compare the five-year cost-effectiveness of imatinib-first vs physician's choice from a US commercial payer perspective, assuming 3% annual discounting ($US 2013). The models' clinical endpoint was five-year overall survival taken from a systematic review of clinical trial results. Per-person spending on incident CML-CP treatment overall care components was estimated using Truven's MarketScan claims data. The main outcome of the models was cost per quality-adjusted life-year (QALY). We interpreted outcomes based on a willingness-to-pay threshold of $100 000/QALY. A panel of European LeukemiaNet experts oversaw the study's conduct. RESULTS: Both strategies met the threshold. Imatinib-first ($277 401, 3.87 QALYs) offered patients a 0.10 decrement in QALYs at a savings of $88 343 over five years to payers compared with physician's choice ($365 744, 3.97 QALYs). The imatinib-first incremental cost-effectiveness ratio was approximately $883 730/QALY. The results were robust to multiple sensitivity analyses. CONCLUSION: When imatinib loses patent protection and its price declines, its use will be the cost-effective initial treatment strategy for CML-CP.
- MeSH
- analýza nákladů a výnosů MeSH
- analýza přežití MeSH
- antitumorózní látky ekonomika terapeutické užití MeSH
- chronická myeloidní leukemie farmakoterapie ekonomika mortalita MeSH
- dospělí MeSH
- ekonometrické modely MeSH
- generika * ekonomika terapeutické užití MeSH
- imatinib mesylát ekonomika terapeutické užití MeSH
- inhibitory proteinkinas ekonomika terapeutické užití MeSH
- kvalitativně upravené roky života MeSH
- lékařská praxe - způsoby provádění * normy trendy MeSH
- lidé středního věku MeSH
- lidé MeSH
- Markovovy řetězce MeSH
- senioři MeSH
- tyrosinkinasy antagonisté a inhibitory MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
- srovnávací studie MeSH
- Geografické názvy
- Spojené státy americké MeSH
Upřesnit dle MeSH
Sdílet
Název dokumentu
Po ukončení testovacího provozu bude odkaz přesměrován adresu produkční verze portálu Medvik.